Aclaris Therapeutics, Inc.
ACRS
$1.75
-$0.06-3.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -47.56% | -42.87% | -40.09% | 27.33% | 3.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -47.56% | -42.87% | -40.09% | 26.35% | 2.72% |
| Cost of Revenue | -37.74% | -50.27% | -57.07% | -41.90% | -19.39% |
| Gross Profit | 31.84% | 53.55% | 63.46% | 59.20% | 28.63% |
| SG&A Expenses | -14.88% | -27.29% | -29.54% | -21.63% | -13.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.40% | -45.09% | -51.12% | -37.27% | -18.09% |
| Operating Income | 26.28% | 45.78% | 54.13% | 49.04% | 24.29% |
| Income Before Tax | -128.05% | -67.73% | -48.64% | 67.40% | 43.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -129.47% | -68.53% | -49.26% | 67.72% | 44.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -129.47% | -68.53% | -49.26% | 67.72% | 44.28% |
| EBIT | 26.28% | 45.78% | 54.13% | 49.04% | 24.29% |
| EBITDA | 26.10% | 45.70% | 54.17% | 37.24% | 4.32% |
| EPS Basic | -65.55% | -28.01% | -18.68% | 68.82% | 46.78% |
| Normalized Basic EPS | 55.54% | 62.57% | 63.20% | 55.09% | 30.95% |
| EPS Diluted | -65.20% | -27.82% | -18.54% | 68.67% | 46.62% |
| Normalized Diluted EPS | 55.54% | 62.57% | 63.20% | 55.09% | 30.95% |
| Average Basic Shares Outstanding | 44.93% | 27.17% | 10.70% | 3.50% | 4.86% |
| Average Diluted Shares Outstanding | 44.93% | 27.17% | 10.70% | 3.50% | 4.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |